Bibliografía del artículo
1. Mathers C, et al. The global burden of disease : 2004 update. 2008, Geneva, Switzerland: World Health Organization. VII. pp. 146.
2. Hutter N, Schnurr A, Baumeister H. Healthcare costs in patients with diabetes mellitus and comorbid mental disorders: a systematic review. Diabetologia 53(12):2470-9.
3. Stuart MJ, Baune BT. Depression and type 2 diabetes: Inflammatory mechanisms of a psychoneuroendocrine co-morbidity. Neurosci Biobehav Rev 36(1):658-76.
4. Mezuk B, et al. Depression and type 2 diabetes over the lifespan: a meta-analysis. Diabetes Care 31(12):2383-90, 2008.
5. van der Feltz-Cornelis CM, et al. Effect of interventions for major depressive disorder and significant depressive symptoms in patients with diabetes mellitus: a systematic review and meta-analysis. Gen Hosp Psychiatry 32(4):380-95.
6. Fraguas R, Soares SM, Bronstein MD. Depression and diabetes mellitus. Revista de Psiquiatria Clínica 36(supl. 3 ):93-99, 2009.
7. Musselman DL, et al. Relationship of depression to diabetes types 1 and 2: epidemiology, biology, and treatment. Biol Psychiatry 54(3):317-29, 2003.
8. Anderson RJ, et al. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care 24(6):1069-78, 2001.
9. Pouwer F, et al. Prevalence of comorbid depression is high in out-patients with Type 1 or Type 2 diabetes mellitus. Results from three out-patient clinics in the Netherlands. Diabet Med 27(2):217-24.
10. Lustman PJ, Griffith LS, Clouse RE. Depression in Adults with Diabetes. Semin Clin Neuropsychiatry 2(1):15-23, 1997.
11. Engum A. The role of depression and anxiety in onset of diabetes in a large population-based study. J Psychosom Res 62(1):31-8, 2007.
12. Eaton WW, et al. Depression and risk for onset of type II diabetes. A prospective population-based study. Diabetes Care 19(10):1097-102, 1996.
13. Kawakami N, et al. Depressive symptoms and occurrence of type 2 diabetes among Japanese men. Diabetes Care 22(7):1071-6, 1999.
14. Everson-Rose SA, et al. Depressive symptoms, insulin resistance, and risk of diabetes in women at midlife. Diabetes Care 27(12):2856-62, 2004.
15. Pouwer F, de Jonge P. Depressive symptoms, insulin resistance, and risk of diabetes in women at midlife: response to Everson-Rose et al. Diabetes Care 28(5):1265-6, 2005.
16. Golden SH, et al. Examining a bidirectional association between depressive symptoms and diabetes. Jama 299(23):2751-9, 2008.
17. Rubin RR, et al. Elevated depression symptoms, antidepressant medicine use, and risk of developing diabetes during the diabetes prevention program. Diabetes Care 31(3):420-426, 2008.
18. Andersohn F, et al. Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am J Psychiatry 166(5):591-8, 2009.
19. Eren I, Erdi O, Sahin M. The effect of depression on quality of life of patients with type II diabetes mellitus. Depress Anxiety 25(2):98-106, 2008.
20. Ciechanowski PS, et al. The relationship of depressive symptoms to symptom reporting, self-care and glucose control in diabetes. Gen Hosp Psychiatry 25(4):246-52, 2003.
21. Egede LE, Osborn CY. Role of motivation in the relationship between depression, self-care, and glycemic control in adults with type 2 diabetes. Diabetes Educ 36(2):276-83.
22. Lustman PJ, et al. Depression and poor glycemic control: a meta-analytic review of the literature. Diabetes Care 23(7):934-42, 2000.
23. Katon WJ, et al. The association of comorbid depression with mortality in patients with type 2 diabetes. Diabetes Care 28(11):2668-72, 2005.
24. Kumar A, et al. Gray matter prefrontal changes in type 2 diabetes detected using MRI. J Magn Reson Imaging 27(1):14-9, 2008.
25. Goodnick PJ. Use of antidepressants in treatment of comorbid diabetes mellitus and depression as well as in diabetic neuropathy. Ann Clin Psychiatry 13(1):31-41, 2001.
26. Lugtenberg M, et al. Current guidelines have limited applicability to patients with comorbid conditions: a systematic analysis of evidence-based guidelines. PLoS One 6(10):e25987.
27. Gloaguen V, et al. A meta-analysis of the effects of cognitive therapy in depressed patients. J Affect Disord 49(1):59-72, 1998.
28. DeRubeis RJ, et al. Medications versus cognitive behavior therapy for severely depressed outpatients: mega-analysis of four randomized comparisons. Am J Psychiatry 156(7):1007-13, 1999.
29. Lustman PJ, et al. Cognitive behavior therapy for depression in type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Méd 129(8):613-21, 1998.
30. Lustman PJ, et al. Predicting response to cognitive behavior therapy of depression in type 2 diabetes. Gen Hosp Psychiatry 20(5):302-6, 1998.
31. Snoek FJ, et al. Cognitive behavioural therapy (CBT) compared with blood glucose awareness training (BGAT) in poorly controlled Type 1 diabetic patients: long-term effects on HbA moderated by depression. A randomized controlled trial. Diabet Méd 25(11):1337-42, 2008.
32. Ismail K, et al. Motivational enhancement therapy with and without cognitive behavior therapy to treat type 1 diabetes: a randomized trial. Ann Intern Méd 149(10):708-19, 2008.
33. van Bastelaar KM, et al. Web-based depression treatment for type 1 and type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 34(2):320-5.
34. Wang MY, et al. A systematic review of the efficacy of non-pharmacological treatments for depression on glycaemic control in type 2 diabetics. J Clin Nurs 17(19):2524-30, 2008.
35. Simson U, et al. Psychotherapy intervention to reduce depressive symptoms in patients with diabetic foot syndrome. Diabet Med 25(2):206-12, 2008.
36. Due-Christensen M, et al. Can sharing experiences in groups reduce the burden of living with diabetes, regardless of glycaemic control? Diabet Med.
37. Williams JW Jr, et al. The effectiveness of depression care management on diabetes-related outcomes in older patients. Ann Intern Méd 140(12):1015-24, 2004.
38. Katon WJ, et al. The Pathways Study: a randomized trial of collaborative care in patients with diabetes and depression. Arch Gen Psychiatry 61(10):1042-9, 2004.
39. Lustman PJ, et al. Fluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trial. Diabetes Care 23(5):618-23, 2000.
40. Paile-Hyvarinen M, Wahlbeck K, Eriksson JG. Quality of life and metabolic status in mildly depressed patients with type 2 diabetes treated with paroxetine: a double-blind randomised placebo controlled 6-month trial. BMC Fam Pract 8:34, 2007.
41. Hardy T, et al. Does treatment with duloxetine for neuropathic pain impact glycemic control? Diabetes Care 30(1):21-6, 2007.
42. Lustman PJ, et al. Sertraline for prevention of depression recurrence in diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry 63(5):521-9, 2006.
43. Echeverry D, et al. Effect of pharmacological treatment of depression on A1C and quality of life in low-income Hispanics and African Americans with diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes Care 32(12):2156-60, 2009.
44. Lustman PJ, et al. Factors influencing glycemic control in type 2 diabetes during acute- and maintenance-phase treatment of major depressive disorder with bupropion. Diabetes Care 30(3):459-66, 2007.
45. Carney C. Diabetes mellitus and major depressive disorder: an overview of prevalence, complications, and treatment. Depress Anxiety 7(4):149-57, 1998.
46. Lustman PJ, et al. Effects of nortriptyline on depression and glycemic control in diabetes: results of a double-blind, placebo-controlled trial. Psychosom Méd 59(3):241-50, 1997.
47. Derijks HJ, et al. The association between antidepressant use and hypoglycaemia in diabetic patients: a nested case-control study. Pharmacoepidemiology and Drug Safety 17(4):336-344, 2008.
48. Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry 71(10):1259-72.
49. Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 166(9):980-91, 2009.
50. Nihalani N, et al. Weight gain, obesity, and psychotropic prescribing. J Obes 2011:893629.
51. Gentile S. A systematic review of quality of life and weight gain-related issues in patients treated for severe and persistent mental disorders: focus on aripiprazole. Neuropsychiatr Dis Treat 5:117-25, 2009.
52. Weiner RD, Sibert TE. Use of ECT in treatment of depression in patients with diabetes mellitus. J Clin Psychiatry 57(3):138, 1996.